Alnylam Pharmaceuticals (ALNY) News Today $481.67 +0.60 (+0.12%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$482.39 +0.72 (+0.15%) As of 10/17/2025 05:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Why Is Alnylam Pharmaceuticals Up Today?Toggle Visibility of Why Is Alnylam Pharmaceuticals Up Today?Alnylam Pharmaceuticals (ALNY) — The stock is trading higher today amid analyst support and momentum headlines, but sentiment is mixed because Leerink/Leerink Partnrs has cut near-term EPS estimates and issued more cautious guidance. Investors are likely reacting to the Truist price‑target lift and a fresh 52‑week high while weighing Leerink's downward revisions ahead of Alnylam's Q3 webcast. Positive Sentiment: Truist raised its price target to $535 and reiterated a "buy" rating, signaling analyst conviction and ~11% implied upside from current levels — a catalyst underpinning the rally. Truist Raises Price Target to $535 Positive Sentiment: Technical momentum: coverage noted ALNY hit a new 52‑week high, which can attract momentum and ETF flows. ALNY Hits New 52-Week High Positive Sentiment: Analysts and press are re‑assessing valuation after reports of new partnerships, pipeline progress and fresh financing — narrative that supports a higher valuation multiple if execution continues. Assessing Valuation Following New Partnerships Neutral Sentiment: Alnylam scheduled a webcast to discuss Q3 2025 results — a near‑term event that will drive volatility and give clarity on revenue/guidance vs. recent analyst revisions. Q3 2025 Webcast Neutral Sentiment: Coverage pieces summarizing Leerink's forecasts (FY2026 discussions) are circulating — useful for investors but not new company data. Leerink FY2026 Forecast Summary Negative Sentiment: Leerink/Leerink Partnrs cut near‑term EPS estimates sharply (Q3 down from $0.38 to $0.03) and lowered FY2025 EPS (to about -$0.10), flagging weaker near‑term earnings outlook that could pressure the stock if confirmed. Leerink Lowers EPS Estimates Negative Sentiment: Leerink reportedly moved to a "hold" view in coverage (coverage note highlighted by press) — a more cautious stance that can limit upside from investor flows even with positive headlines. Leerink Issues Hold Bottom line for investors: upside today is driven by the Truist upgrade, valuation/pipeline optimism and technical strength; watch the Q3 webcast and Leerink's lowered near‑term EPS assumptions for confirmation — those items are the most likely near‑term drivers of further moves in ALNY.Posted 1+ days agoAI Generated. May Contain Errors. ALNY Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period Truist Securities Maintains Alnylam Pharmaceuticals (ALNY) Buy RecommendationOctober 18 at 10:49 AM | msn.comTruist Financial Issues Positive Forecast for Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock PriceOctober 18 at 10:11 AM | marketbeat.comSagespring Wealth Partners LLC Makes New $299,000 Investment in Alnylam Pharmaceuticals, Inc. $ALNYOctober 18 at 4:30 AM | marketbeat.comWilmington Savings Fund Society FSB Has $550,000 Stake in Alnylam Pharmaceuticals, Inc. $ALNYOctober 18 at 4:16 AM | marketbeat.comLeerink Partnrs Brokers Lower Earnings Estimates for ALNYOctober 18 at 2:57 AM | americanbankingnews.comAlnylam Pharma (ALNY) Gets a Hold from Leerink PartnersOctober 17 at 8:46 PM | theglobeandmail.comValues First Advisors Inc. Sells 4,166 Shares of Alnylam Pharmaceuticals, Inc. $ALNYOctober 17 at 6:02 AM | marketbeat.comAllianz Asset Management GmbH Reduces Stock Position in Alnylam Pharmaceuticals, Inc. $ALNYOctober 17 at 5:16 AM | marketbeat.comSequoia Financial Advisors LLC Boosts Stake in Alnylam Pharmaceuticals, Inc. $ALNYOctober 17 at 4:06 AM | marketbeat.comWhat is Leerink Partnrs' Forecast for ALNY FY2026 Earnings?October 17 at 2:59 AM | americanbankingnews.comAlnylam Pharmaceuticals (ALNY): Assessing Valuation Following New Partnerships, Pipeline Progress, and Fresh FinancingOctober 16 at 4:37 PM | finance.yahoo.comAlnylam Pharmaceuticals (NASDAQ:ALNY) Hits New 52-Week High - What's Next?October 16 at 3:18 PM | marketbeat.comAlnylam to Webcast Conference Call Discussing Third Quarter 2025 Financial ResultsOctober 16 at 11:35 AM | finance.yahoo.comLeerink Partnrs Issues Negative Outlook for ALNY EarningsOctober 16 at 7:15 AM | marketbeat.comWhat Catalysts Are Shaping the Evolving Narrative for Alnylam Pharmaceuticals?October 15, 2025 | finance.yahoo.comLeerink Partnrs Issues Optimistic Forecast for ALNY EarningsOctober 15, 2025 | marketbeat.comTD Asset Management Inc Sells 45,407 Shares of Alnylam Pharmaceuticals, Inc. $ALNYOctober 15, 2025 | marketbeat.comVanguard Personalized Indexing Management LLC Acquires 4,302 Shares of Alnylam Pharmaceuticals, Inc. $ALNYOctober 15, 2025 | marketbeat.comJPMorgan Chase & Co. Issues Pessimistic Forecast for Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock PriceOctober 15, 2025 | americanbankingnews.com$1000 Invested In Alnylam Pharmaceuticals 10 Years Ago Would Be Worth This Much TodayOctober 14, 2025 | benzinga.comPerfromance Wealth Partners LLC Makes New Investment in Alnylam Pharmaceuticals, Inc. $ALNYOctober 14, 2025 | marketbeat.comAlnylam Pharmaceuticals, Inc. $ALNY Shares Acquired by Allspring Global Investments Holdings LLCOctober 14, 2025 | marketbeat.comJP Morgan Maintains Alnylam Pharmaceuticals (ALNY) Overweight RecommendationOctober 14, 2025 | msn.comThis Pharma Play, The IBD Stock Of The Day, Is Offering Another Entry Amid 100% Advance This YearOctober 13, 2025 | msn.comStifel Nicolaus Sticks to Its Hold Rating for Ionis Pharmaceuticals (IONS)October 13, 2025 | theglobeandmail.comAlnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Lowered to $473.00 at JPMorgan Chase & Co.October 13, 2025 | marketbeat.comCallan Family Office LLC Raises Stake in Alnylam Pharmaceuticals, Inc. $ALNYOctober 13, 2025 | marketbeat.comVontobel Holding Ltd. Has $951,000 Position in Alnylam Pharmaceuticals, Inc. $ALNYOctober 13, 2025 | marketbeat.comSivik Global Healthcare LLC Takes Position in Alnylam Pharmaceuticals, Inc. $ALNYOctober 12, 2025 | marketbeat.comAberdeen Group plc Boosts Holdings in Alnylam Pharmaceuticals, Inc. $ALNYOctober 12, 2025 | marketbeat.comAlnylam Pharmaceuticals (NASDAQ:ALNY) Downgraded by Wall Street Zen to BuyOctober 12, 2025 | marketbeat.comAlnylam Pharmaceuticals (NASDAQ:ALNY) Receives Buy Rating from HC WainwrightOctober 11, 2025 | marketbeat.comHC Wainwright & Co. Reiterates Alnylam Pharmaceuticals (ALNY) Buy RecommendationOctober 10, 2025 | msn.comBrokerages Set Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) PT at $448.04October 10, 2025 | americanbankingnews.comShell Asset Management Co. Purchases 1,602 Shares of Alnylam Pharmaceuticals, Inc. $ALNYOctober 9, 2025 | marketbeat.comKLP Kapitalforvaltning AS Has $16.01 Million Stock Position in Alnylam Pharmaceuticals, Inc. $ALNYOctober 9, 2025 | marketbeat.comMirae Asset Global Investments Co. Ltd. Has $1.56 Million Stock Position in Alnylam Pharmaceuticals, Inc. $ALNYOctober 9, 2025 | marketbeat.comWeiss Ratings Reaffirms "Sell (D-)" Rating for Alnylam Pharmaceuticals (NASDAQ:ALNY)October 8, 2025 | marketbeat.comAlnylam Pharmaceuticals (NASDAQ:ALNY) Stock Price Expected to Rise, Stifel Nicolaus Analyst SaysOctober 8, 2025 | americanbankingnews.comAlnylam Pharma (ALNY) Gets a Hold from Morgan StanleyOctober 7, 2025 | theglobeandmail.comRNAi: The Benefits Of Shooting The MessengerOctober 7, 2025 | seekingalpha.comStifel Maintains Alnylam Pharmaceuticals (ALNY) Buy RecommendationOctober 7, 2025 | msn.comMorgan Stanley Maintains Alnylam Pharmaceuticals (ALNY) Equal-Weight RecommendationOctober 7, 2025 | msn.comAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Given Average Recommendation of "Moderate Buy" by BrokeragesOctober 7, 2025 | marketbeat.comMorgan Stanley Raises Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target to $475.00October 6, 2025 | marketbeat.comAlnylam Pharmaceuticals (NASDAQ:ALNY) Given New $495.00 Price Target at Stifel NicolausOctober 6, 2025 | marketbeat.comAMF Tjanstepension AB Makes New $10.61 Million Investment in Alnylam Pharmaceuticals, Inc. $ALNYOctober 4, 2025 | marketbeat.comInsider Selling: Alnylam Pharmaceuticals (NASDAQ:ALNY) EVP Sells 1,405 Shares of StockOctober 4, 2025 | insidertrades.comRobeco Institutional Asset Management B.V. Trims Holdings in Alnylam Pharmaceuticals, Inc. $ALNYOctober 4, 2025 | marketbeat.comAlnylam Pharmaceuticals (NASDAQ:ALNY) Upgraded to Strong-Buy at Wall Street ZenOctober 4, 2025 | marketbeat.com Get Alnylam Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ALNY and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ALNY Media Mentions By Week ALNY Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ALNY News Sentiment▼0.730.48▲Average Medical News Sentiment ALNY News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ALNY Articles This Week▼3523▲ALNY Articles Average Week Get the Latest News and Ratings for ALNY and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Alnylam Pharmaceuticals and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Amgen News Gilead Sciences News Vertex Pharmaceuticals News Regeneron Pharmaceuticals News Biogen News United Therapeutics News Incyte News Neurocrine Biosciences News Ionis Pharmaceuticals News Exact Sciences News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ALNY) was last updated on 10/19/2025 by MarketBeat.com Staff From Our PartnersCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredBuy alert: Move $1,000 before Tesla’s Optimus launchElon's $1,000,000,000,000 payday Elon Musk just made his biggest insider purchase of Tesla stock ever. He's...Altimetry | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alnylam Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alnylam Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.